What happened
Kyongbo Pharmaceutical filed provisional (unaudited) separate results for Q2 2026: revenue of US$53M (+15.2% year on year), operating profit of US$655K (−61.4% year on year) and net income of US$2.09M (from a loss a year earlier).
These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.
| Revenue | US$53M |
|---|---|
| Revenue vs a year earlier | +15.2% |
| Operating profit | US$655K |
| Net income | US$2.09M |
| Period | Q2 2026 (separate) |
| Filed | 2026-07-31, Operating results (preliminary) (fair disclosure) |
| Source | DART rcept 20260731800820 → open original filing |
Source: DART. Information only, not investment advice.